##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 124 Download : 95

##plugins.themes.academic_pro.article.main##

Abstract

Background: Jaundice is observed in first week of life in 60% of term & 80% of preterm infants, it is usually benign, but untreated, severe indirect hyperbilirubinemia is potentially toxic to nervous system of neonate.


Aim of the study: Identify the factors affecting the lines of management of neonatal jaundice.


Patients &Methods: this cross sectional study was carried out at neonatal intensive care unit (NICU) of Children's Hospital in the City of Kirkuk, Iraq; from May 2020 to November 2020.Data were collected from228 admission records. The age of patients were 1 day to 28 days.


Results: from 228 neonate ,166(72%) had neonatal jaundice,128(77.1%)were term ,38(22.8%) were preterm, the factors studied were (level of total serum bilirubin TSB ,term ,preterm ,age of neonate ,& weight) with lines of management used in NICU (phototherapy ,antibiotics ,combined phototherapy with antibiotics ,& exchange transfusion ).There was a significant association between these factors & the lines of management applied .


Conclusion: level of serum bilirubin is the most important factor in the management and the study showed a significant association between level of serum bilirubin and the other factors studied with the lines of management


Recommendation: Educating families about early recognition of jaundice &seeking medical advice is important to avoid invasive procedures like exchange transfusion and it is be better to start phototherapy earlier &at lower TSB level in low birth weight babies

Keywords

Jaundice TSB Term Preterm

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Sayran Atallah Faiq, & May Mohammed Sheriff. (2022). Neonatal Jaundice: Lines of Management in Children’s Hospital at Kirkuk city, Iraq. Texas Journal of Medical Science, 9, 1–7. https://doi.org/10.62480/tjms.2022.vol9.pp1-7
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Stoll B J.Kliegman RM . Jaundice and hyperbilirubinemia in the newborn. In: Beherman RE,Kliegman RM ,Jensen HB ,eds.Nelson Textbook of Pediatrics .17th ed. WB Saunders Co :Philadelphia PA:2004:91:592-599.
  2. Saeidi R. Heydarian F.,Fakehi V.,Role of intravenous extra fluid therapy in icteric neonates receiving phototherapy .Saudi Med J,2009;30:1176-1178.
  3. Maisels MJ. Jaundice in the newborn .Pediatrics in Review.2006; 27:443-455.
  4. Weinberg R P.Gastroenterology. I.Bilirubin physiology In:Roberton NRC.ed.Textbook of neonatology.London: Churchill Livingstone; 1986:383-393.
  5. Amin SB. ,Lamola AA.,Newborn jaundice and bilirubin binding capacity in neonate, Semin Perinatol .2011;35(3):134-140.
  6. Dennery PA.,Seidman DS., Stevenson DK. Neonatal hyper bilirubinemia . N Engl Med 2001:344:581-590 .
  7. Maisels MJ.,Baltz RD ,Bhutani V,et al.Management of hyperbilirubinemia in the newborn infant 35or more weeks of gestation. Pediatrics.2004;114:297-316.
  8. Watchko JF. hyperbilirubinemia and bilirubin toxicity in the late preterm infant. Clin Perinatol .2006 ;33(4):839-852.
  9. Wang X.,RoyChowdhury J.,RoyChowdhury N.Bilirubin metabolism:Applied physiology.Curr Pediatr .2006;16:70-74.
  10. XiangT.,Qu Y.,Cambiers S.,et al. The side effects of phototherapy for neonatal jaundice:what do we know?what should we do?.Eur J Pediatr .2011; 1:338-339.
  11. Watchko JF. Neonatal hyperbilirubinemia –what are the risks? N Engl Med. 2006;354:1947-1949.
  12. MacDongh AF., Palmer LA., Lightner DA. Phototherapy for neonatal jaundice. J Am Chem Soc.1982;104:6867.
  13. Ennever JF.Blue light,green light,white light ,more light:treatment of neonatal jaundice.Clin Perinatol ,1990;17:467-481.